Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-17
2007-04-17
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000
Reexamination Certificate
active
11244772
ABSTRACT:
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 5571813 (1996-11-01), Ruhter et al.
patent: 5602136 (1997-02-01), Ruhter et al.
patent: 5602137 (1997-02-01), Ruhter et al.
patent: 5688949 (1997-11-01), Inoue et al.
patent: 5707997 (1998-01-01), Shoji et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 6040321 (2000-03-01), Kim et al.
patent: 6191131 (2001-02-01), He et al.
patent: 6262096 (2001-07-01), Kim et al.
patent: 6413974 (2002-07-01), Dumont et al.
patent: 10223917 (2003-12-01), None
patent: 0591528 (1994-04-01), None
patent: 0628559 (2002-04-01), None
patent: 1334973 (2003-08-01), None
patent: 03204877 (1991-09-01), None
patent: WO 95/35298 (1995-12-01), None
patent: WO 02/40485 (2002-05-01), None
patent: WO 02/50079 (2002-06-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 03/091258 (2003-11-01), None
patent: WO 2004/022559 (2004-03-01), None
patent: WO 2004/076458 (2004-09-01), None
Fischer, P.M.; Gianella-Borradori, A.; CDK inhibitors in clinical development for the treatment of cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970.
Fischer, P.M.; Gianella-Borradori, A.; Recent progress in the discovery and development of cyclin-dependent kinase inhibitors, Expert. Opin. Investig. Drugs; 2005; 14(4); 457-477.
Senderowicz et al., “Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators”, J. National Cancer Institute (Mar. 1, 2000), 96(5): 376-387.
Veseley et al., “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”, Eur. J. Biochem. (1994), 224: 771-786.
Kim et al., “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2; Synthesis . . . ”, Journal of Medicinal Chemistry (2002), 45: 3905-3927.
Mettey et al., “Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in . . . ” J. Med. Chem. (2003), 46: 222-236.
Novinson et al., “Synthesis and Antifungal Properites of Certain . . . ”, Journal of Medicinal Chemistry (1977), 20(2): 296-299.
Senderowicz et al., “Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent . . . ”, Journal of Clinical Oncology (Sep. 1998), 16(9): 2966-2999.
Miejer et al., “Biochemical and cellular effects of roscovitine, a potent and selective inhibitor . . . ”, Eur. J. Biochem. (1997), 243: 527-536.
Bible et al., “Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8276) and Various Antineoplastic . . . ”, Cancer Research (Aug. 15, 1997), 57: 3375-3380.
Shiota et al., “Synthesis and Structure-Acitvity Relationship of a New Series of Potent Angiotensin . . . ”, Chem. Pharm. Bull. (1999), 47(7): 928-938.
Yasuo Maksumi, “Studies on the Azalndolizine Compounds . . . ”, Chem. Pharm. Bull. (1962), 10:620-626.
Dwyer Michael P.
Guzi Timothy J.
Paruch Kamil
Berch Mark L.
Kalyanaraman Palaiyur S.
Moore Susanna
Schering Corporation
LandOfFree
Trisubstituted 7-aminopyrazolopyrimidines as cyclin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trisubstituted 7-aminopyrazolopyrimidines as cyclin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trisubstituted 7-aminopyrazolopyrimidines as cyclin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3760805